secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001799191-24-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M
--------------------------------------------------------------------------------

- Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.
- Gross profit $14.4M (-10.1% YoY); SG&A reduced 6% to $26.6M.
- Net loss $16.1M ($0.18 EPS) vs $17.4M loss in Q3 2023.
- Adjusted EBITDA -$8.2M vs -$5.3M in prior year period.
- Board completed strategic review; elected to continue current plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000179919124000028/0001799191-24-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000179919124000028/toi-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001799191-24-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer